Skip to content

Clinical trials

Phase 3 Non-Muscle Invasive Bladder Neoplasms trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Non-Muscle Invasive Bladder Neoplasms Phase: Phase 3 Clear all

44 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20021
20101
20112
20121
20154
20163
20172
20181
20191
20201
20214
20221
20234
20244
20256
20265

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Recruiting10
Active, not recruiting9
Terminated8
Completed6
Withdrawn5
Not yet recruiting3
Unknown status3

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
UroGen Pharma Ltd.4
Janssen Research & Development, LLC3
Medical Enterprises Europe B.V.3
Spectrum Pharmaceuticals, Inc3
AstraZeneca2
CG Oncology, Inc.2
Jiangsu Yahong Meditech Co., Ltd aka Asieris2
Relmada Therapeutics, Inc.2
Abnoba Gmbh1
Affiliated Cancer Hospital & Institute of Guangzhou Medical University1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Non-Muscle Invasive Bladder Neoplasms44
Urinary Bladder Neoplasms23
Carcinoma, Transitional Cell7
Neoplasms7
Urologic Neoplasms6
Carcinoma in Situ4
Neoplasms by Site3
Urinary Bladder Diseases3
Urologic Diseases3
Urogenital Neoplasms2

Trials

Showing 76 to 44 of 44. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.